Results 61 to 70 of about 45,683 (251)
Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study
Movement Disorders, EarlyView.Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri +13 more
wiley +1 more source
Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey
Harm Reduction JournalBackground The rising prevalence of fast-acting opioids in the USA suggests the increased need for non-professional first responder administration of naloxone.
Spencer Cooper-Ohm +3 more
doaj +1 more source
Preventing opioid overdose with peer-administered naloxone: findings from a rural state
Harm Reduction Journal, 2020 Background In response to the opioid epidemic, naloxone distribution programs aim to prevent overdose death by making naloxone available and training people to use it.
Bridget L. Hanson +3 more
doaj +1 more source
BMC Public Health, 2021 Background Opioid related overdoses and overdose deaths continue to constitute an urgent public health crisis. The implementation of naloxone programs, such as ‘take-home naloxone’ (THN), has emerged as a key intervention in reducing opioid overdose ...
Amina Moustaqim-Barrette +9 more
doaj +1 more source
Movement Disorders, EarlyView.Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota +14 more
wiley +1 more source
Use of urinary naloxone levels in a single provider practice: a case study
Addiction Science & Clinical Practice, 2020 Background Urine drug monitoring for medications for opioid use disorder (MOUD) such as buprenorphine can help to support treatment adherence. The practice of introducing unconsumed medication directly into urine (known as “spiking” samples) has been ...
Jill S. Warrington +3 more
doaj +1 more source
Medicinal Research Reviews, EarlyView.ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu +15 more
wiley +1 more source
Messaging to Increase Public Support for Naloxone Distribution Policies in the United States: Results from a Randomized Survey Experiment. [PDF]
PLoS ONE, 2015 Barriers to public support for naloxone distribution include lack of knowledge, concerns about potential unintended consequences, and lack of sympathy for people at risk of overdose.A randomized survey experiment was conducted with a nationally ...
Marcus A Bachhuber +4 more
doaj +1 more source
Small, EarlyView.Force‐driven microneedles are presented as active therapeutic microdevices that overcome the diffusion limits of conventional patches. By integrating gas generation, magnetic actuation, cavitation, or iontophoresis, these systems drive payloads deeper into tissue, enabling faster, more controlled delivery and highlighting key design principles and ...
Majed Amini +3 more
wiley +1 more source
Legal gems: Supply of S3 naloxone
, 2017 In February 2016, naloxone 400 mcg/mL was rescheduled for supply as a Schedule 3 (S3; Pharmacist Only) medication for the treatment of opioid overdose. For all other purposes, naloxone remains a Schedule 4 (S4; Prescription Only) medication.
Dickfos, Steven T +2 more
core +1 more source